CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Alnylam Pharmaceuticals, Inc. - ALNY CFD

152.54
1.63%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.41
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Alnylam Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 150.1
Open* 150.12
1-Year Change* -21.62%
Day's Range* 150.12 - 155.18
52 wk Range 148.10-234.78
Average Volume (10 days) 575.54K
Average Volume (3 months) 11.90M
Market Cap 23.34B
P/E Ratio -100.00K
Shares Outstanding 125.49M
Revenue 1.72B
EPS -4.18
Dividend (Yield %) N/A
Beta 0.44
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 152.54 3.14 2.10% 149.40 155.57 148.52
Feb 29, 2024 150.10 -5.43 -3.49% 155.53 156.64 148.64
Feb 28, 2024 154.34 -1.84 -1.18% 156.18 157.57 153.71
Feb 27, 2024 158.84 0.47 0.30% 158.37 160.98 157.34
Feb 26, 2024 158.57 3.36 2.16% 155.21 158.76 153.53
Feb 23, 2024 157.47 -4.17 -2.58% 161.64 162.65 155.44
Feb 22, 2024 162.62 9.55 6.24% 153.07 163.85 152.42
Feb 21, 2024 154.63 5.98 4.02% 148.65 155.24 148.40
Feb 20, 2024 149.59 3.34 2.28% 146.25 149.94 144.94
Feb 16, 2024 146.85 -1.06 -0.72% 147.91 150.04 146.52
Feb 15, 2024 147.27 -1.47 -0.99% 148.74 152.70 142.72
Feb 14, 2024 163.10 1.34 0.83% 161.76 164.51 160.28
Feb 13, 2024 161.81 -2.13 -1.30% 163.94 166.18 160.45
Feb 12, 2024 169.01 0.58 0.34% 168.43 171.01 166.64
Feb 9, 2024 169.23 1.68 1.00% 167.55 171.47 167.55
Feb 8, 2024 169.35 0.97 0.58% 168.38 170.03 165.06
Feb 7, 2024 168.32 -2.94 -1.72% 171.26 172.08 167.44
Feb 6, 2024 171.05 1.79 1.06% 169.26 173.01 169.25
Feb 5, 2024 170.60 0.08 0.05% 170.52 172.47 167.94
Feb 2, 2024 172.86 0.92 0.54% 171.94 174.28 168.75

Alnylam Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

14:10

Country

US

Event

Alnylam Pharmaceuticals Inc at TD Cowen Health Care Conference
Alnylam Pharmaceuticals Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Alnylam Pharmaceuticals Inc Earnings Release
Q1 2024 Alnylam Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

12:30

Country

US

Event

Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1037.42 844.287 492.853 219.75 74.908
Revenue 1037.42 844.287 492.853 219.75 74.908
Total Operating Expense 1899.08 1552.94 1321.29 1159.18 869.017
Selling/General/Admin. Expenses, Total 770.658 620.639 588.42 479.005 382.359
Research & Development 883.015 792.156 654.819 655.114 505.42
Operating Income -861.658 -708.652 -828.438 -939.431 -794.109
Interest Income (Expense), Net Non-Operating -259.131 -124.18 -72.687 33.448 29.262
Other, Net -6.204 -19.312 45.525 20.73 4.173
Net Income Before Taxes -1126.99 -852.144 -855.6 -885.253 -760.674
Net Income After Taxes -1131.16 -852.824 -858.281 -886.116 -762.297
Net Income Before Extra. Items -1131.16 -852.824 -858.281 -886.116 -762.297
Net Income -1131.16 -852.824 -858.281 -886.116 -761.497
Income Available to Common Excl. Extra. Items -1131.16 -852.824 -858.281 -886.116 -762.297
Income Available to Common Incl. Extra. Items -1131.16 -852.824 -858.281 -886.116 -761.497
Diluted Net Income -1131.16 -852.824 -858.281 -886.116 -761.497
Diluted Weighted Average Shares 121.689 118.451 114.986 109.264 100.59
Diluted EPS Excluding Extraordinary Items -9.29547 -7.1998 -7.46422 -8.10986 -7.57826
Diluted Normalized EPS -8.88638 -7.1998 -7.46422 -8.10986 -7.71114
Total Extraordinary Items 0.8
Cost of Revenue, Total 168.817 140.144 78.052 25.062 1.802
Gross Profit 868.601 704.143 414.801 194.688 73.106
Unusual Expense (Income) 76.586 0 -20.564
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 318.754 319.29 335.035 264.306 224.818
Revenue 318.754 319.29 335.035 264.306 224.818
Cost of Revenue, Total 85.37 54.869 51.266 41.116 40.808
Gross Profit 233.384 264.421 283.769 223.19 184.01
Total Operating Expense 548.585 469.097 523.649 598.932 416.504
Selling/General/Admin. Expenses, Total 214.689 183.659 210.344 235.859 169.984
Research & Development 248.526 230.569 262.039 245.371 205.712
Operating Income -229.831 -149.807 -188.614 -334.626 -191.686
Interest Income (Expense), Net Non-Operating -37.775 -19.038 -32.923 -66.198 -73.717
Other, Net -6.603 -3.517 14.516 -5.119 -9.27
Net Income Before Taxes -274.209 -172.362 -207.021 -405.943 -274.673
Net Income After Taxes -276.024 -174.101 -207.493 -405.92 -277.402
Net Income Before Extra. Items -276.024 -174.101 -207.493 -405.92 -277.402
Net Income -276.024 -174.101 -207.493 -405.92 -277.402
Income Available to Common Excl. Extra. Items -276.024 -174.101 -207.493 -405.92 -277.402
Income Available to Common Incl. Extra. Items -276.024 -174.101 -207.493 -405.92 -277.402
Diluted Net Income -276.024 -174.101 -207.493 -405.92 -277.402
Diluted Weighted Average Shares 124.659 124.111 123.282 122.166 120.896
Diluted EPS Excluding Extraordinary Items -2.21423 -1.40278 -1.68308 -3.32269 -2.29455
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.21423 -1.40278 -1.68308 -2.91521 -2.29455
Unusual Expense (Income) 0 76.586
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2692.25 2808.58 2614.78 1715.86 1200.7
Cash and Short Term Investments 2192.41 2435.56 1874.4 1536.16 1084.16
Cash & Equivalents 866.394 819.975 496.58 547.178 420.146
Short Term Investments 1326.01 1615.59 1377.81 988.984 664.009
Total Receivables, Net 237.963 198.571 602.413 43.011 18.76
Accounts Receivable - Trade, Net 205.621 125.305 68.871 43.011 18.76
Prepaid Expenses 132.916 88.078 62.767 80.343 73.713
Total Assets 3546.36 3643.3 3407.06 2395.13 1574.8
Property/Plant/Equipment, Total - Net 738.63 733.633 706.514 646.376 320.658
Property/Plant/Equipment, Total - Gross 912.08 874.048 810.861 722.534 400.143
Accumulated Depreciation, Total -173.45 -140.415 -104.347 -76.158 -79.485
Long Term Investments
Other Long Term Assets, Total 115.482 101.095 85.77 32.894 53.448
Total Current Liabilities 767.915 695.71 585.27 352.594 179.494
Accounts Payable 98.094 73.426 51.966 49.884 59.708
Accrued Expenses 587.427 435.722 392.781 224.889 112.719
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 82.394 186.562 140.523 77.821 7.067
Total Liabilities 3704.58 3055.1 2390.81 956.442 272.837
Total Long Term Debt 1016.94 675.697 191.278 0 30
Long Term Debt 1016.94 675.697 191.278 0 30
Other Liabilities, Total 1919.72 1683.69 1614.27 603.848 63.343
Total Equity -158.223 588.203 1016.25 1438.69 1301.96
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 1.24 1.202 1.164 1.122 1.011
Additional Paid-In Capital 6454.54 6058.45 5644.07 5201.18 4175.14
Retained Earnings (Accumulated Deficit) -6569.35 -5438.19 -4585.37 -3727.09 -2840.97
Other Equity, Total -2.392 1.163 -11.178 -3.863 -33.213
Total Liabilities & Shareholders’ Equity 3546.36 3643.3 3407.06 2395.13 1574.8
Total Common Shares Outstanding 123.925 120.182 116.427 112.188 101.177
Total Inventory 128.962 86.363 75.202 56.348 24.068
Unrealized Gain (Loss) -42.262 -34.422 -32.444 -32.655
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 2985.45 2524.05 2541.02 2692.25 2690.85
Cash and Short Term Investments 2406.28 2057.51 2070.68 2192.41 2265.33
Cash & Equivalents 1033.02 657.8 672.245 866.394 1073.23
Short Term Investments 1373.25 1399.71 1398.43 1326.01 1192.1
Total Receivables, Net 325.445 220.635 219.434 237.963 184.513
Accounts Receivable - Trade, Net 208.998 192.5 196.862 205.621 162.58
Total Inventory 95.771 100.453 131.879 128.962 115.489
Prepaid Expenses 157.958 145.452 119.03 132.916 125.516
Total Assets 3839.07 3402.4 3391.94 3546.36 3535.25
Property/Plant/Equipment, Total - Net 729.076 736.275 738.081 738.63 733.623
Other Long Term Assets, Total 124.545 142.074 112.841 115.482 110.785
Total Current Liabilities 949.785 788.639 673.391 767.915 772.791
Accounts Payable 73.84 59.746 62.237 98.094 40.572
Accrued Expenses 754.61 640.604 551.654 587.427 552.16
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 121.335 88.289 59.5 82.394 180.059
Total Liabilities 4004.94 3810.53 3651.18 3704.58 3602.89
Total Long Term Debt 1019.81 1018.84 1017.89 1016.94 1015.97
Long Term Debt 1019.81 1018.84 1017.89 1016.94 1015.97
Other Liabilities, Total 2035.34 2003.05 1959.9 1919.72 1814.13
Total Equity -165.866 -408.131 -259.24 -158.223 -67.638
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 1.255 1.25 1.243 1.24 1.23
Additional Paid-In Capital 6736.94 6647.17 6522.09 6454.54 6336.77
Retained Earnings (Accumulated Deficit) -6871.72 -7019.47 -6743.45 -6569.35 -6361.86
Unrealized Gain (Loss) -38.284 -40.162 -38.137 -42.262 -45.426
Other Equity, Total 5.945 3.082 -0.987 -2.392 1.643
Total Liabilities & Shareholders’ Equity 3839.07 3402.4 3391.94 3546.36 3535.25
Total Common Shares Outstanding 125.454 124.901 124.241 123.925 122.991
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -1131.16 -852.824 -858.281 -886.116 -761.497
Cash From Operating Activities -541.274 -641.693 -614.961 -278.427 -562.616
Cash From Operating Activities 44.468 47.567 34.772 17.175 6.435
Non-Cash Items 580.967 326.387 221.249 188.133 147.347
Cash Taxes Paid 2.566 1.066
Cash Interest Paid 45.235 24.657 0.172 0.775
Changes in Working Capital -35.553 -162.823 -12.701 402.381 45.099
Cash From Investing Activities 169.354 -273.3 -435.518 -417.677 272.945
Capital Expenditures -72.059 -76.372 -70.361 -140.156 -126.887
Other Investing Cash Flow Items, Total 241.413 -196.928 -365.157 -277.521 399.832
Cash From Financing Activities 425.753 1247.12 994.979 823.184 65.47
Issuance (Retirement) of Stock, Net 259.36 246.268 299.982 853.184 65.47
Issuance (Retirement) of Debt, Net 135.393 500 200 -30
Net Change in Cash 46.403 323.107 -50.582 126.997 -224.201
Foreign Exchange Effects -7.43 -9.018 4.918 -0.083
Financing Cash Flow Items 31 500.85 494.997
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -174.101 -1131.16 -923.663 -517.743 -240.341
Cash From Operating Activities -166.475 -541.274 -409.296 -294.012 -171.193
Cash From Operating Activities 14.065 44.468 30.157 19.557 9.46
Non-Cash Items 79.698 580.967 506.088 230.706 119.651
Changes in Working Capital -86.137 -35.553 -21.878 -26.532 -59.963
Cash From Investing Activities -76.217 169.354 309.265 -4.626 -147.419
Capital Expenditures -13.891 -72.059 -50.424 -33.914 -17.859
Other Investing Cash Flow Items, Total -62.326 241.413 359.689 29.288 -129.56
Cash From Financing Activities 46.371 425.753 362.316 65.293 34.956
Financing Cash Flow Items 4 31 23.5 15.667 7.833
Issuance (Retirement) of Stock, Net 42.371 259.36 202.646 49.626 27.123
Issuance (Retirement) of Debt, Net 135.393 136.17 0
Foreign Exchange Effects 2.176 -7.43 -9.049 -11.073 -2.238
Net Change in Cash -194.145 46.403 253.236 -244.418 -285.894
Cash Interest Paid 13.912 45.235 43.932 29.06
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Capital World Investors Investment Advisor 13.198 16497551 21350 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 9.8262 12282788 -711340 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.2582 11572826 21873 2023-06-30 LOW
Baillie Gifford & Co. Investment Advisor 6.7137 8392216 -246925 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.8542 6067793 -85984 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.7136 5891989 -66528 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.0401 3800092 -88332 2023-06-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 3.0316 3789525 -105010 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 2.5901 3237624 206803 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.3138 2892247 37366 2023-06-30 LOW
Capital International Investors Investment Advisor 2.3045 2880643 651054 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 1.9345 2418143 27576 2023-06-30 LOW
Capital Research Global Investors Investment Advisor 1.8838 2354761 -84835 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4416 1802022 63907 2023-06-30 LOW
RTW Investments L.P. Investment Advisor/Hedge Fund 1.3467 1683362 0 2023-06-30 LOW
Morgan Stanley & Co. LLC Research Firm 1.1251 1406333 649648 2023-06-30 MED
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 0.884 1105000 0 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8103 1012846 -271931 2022-12-31 LOW
Bellevue Asset Management AG Investment Advisor 0.7197 899650 16400 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.6387 798389 67367 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alnylam Company profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Industry: Biotechnology & Medical Research (NEC)

675 W Kendall St
CAMBRIDGE
MASSACHUSETTS 02142-1168
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.64 Price
-1.000% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,083.15 Price
+1.890% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading